This Web Site is committed to the memory of Janis Morrow.

  

HCV News Archives  Index

2001-2002

Back To Latest News

---

JANUARY 2002/2001

---

 

Hepatzyme: Saftey Analysis of Phase I Study

Levothyroxine use could increase number of transplantable donor organs
Second group announces 'knock out' cloned pigs

Round Up the Unusual Suspects

Man who came out on public TV dies at 50 Lilly and Vertex Pharmaceuticals Select Novel Oral Anti-Hepatitis C Summary of FDA Peg-Intron Hearing Expanding the Donor Pool with Living Donors
Hepatitis C Research Gets a Boost
1F7 Shows Positive Data for Hepatitis Heavy Demand Strains Schering? First Monoclonal Antibody to Show Activity Against The Hep C Virus
Research To Understand Poor Outcome In African-Americans/Asian Liver Transplants

Idun Pharmaceuticals' Clinical Trial Demonstrates Safety Of Liver Disease Drug
Roche confident new data will let Pegasys drug fly

February  2002

2002Community Notice: Procedure to avoid missing doses on the PEG-Intron Access Assurance Program
Amarillo Biosciences to Receive Patent on Solid Dosage Forms of Interferon; Company Also Obtains Additional Funding Through Private Placement
New Drugs for Treatment of Chronic Hepatitis C
Hepatitis Screenings Could Save Money, Lives
Study Reports Hepatitis C Impairs Cognitive Functioning: memory, concentration, depression
Phlebotomy May Delay Progression of Liver Fibrosis in Chronic Hepatitis C Patients
How Green Tea May Fight Inflammation
FDA Probes Anti-Anxiety Herb

---

July 2002

---

Study: Hepatitis C Patients Infected After Age 30 Far More Likely to Develop Cirrhosis

Study: HAART Therapy Effective for Both Hepatitis C and HIV Patients

Bayer Seeks FDA Approval of Hepatitis C Test

Discovery Could One Day Lead to Genetic Treatment for Hepatitis C, Other Diseases

Study Set of Use of Human Liver Cells to Treat Cirrhosis Patients

Enbrel Helps Chronic Hepatitis C Patients With Rheumatoid Arthritis

SELECTED HIGHLIGHTS FROM THE DRAFT NIH HCV CONSENSUS STATEMENT

Roche's Hepatitis-C Drug Pegasys Gets EU Approval

Rigel to Present Update on Hepatitis C Drug Development Program

Par Pharmaceutical Announces Licensing of Ribavirin From Three Rivers
Pharmaceutical-Anda Filing with

Paragraph IV Certification May Offer
Co-Exclusive Marketing Rights

---

August 2002

---

Review: New Edition of Living with Hepatitis C Offers Chapter on Pegylated Interferons

Study: Alcohol, Drug Use, Mental Illness More Common in Hepatitis C Patients

Genetic Variation Protects HCV Patients Against Severe Liver Damage

Long-Term Use of Drug Won't Lead to Resistance in HBV Patients

UK: Alcohol-Liver Deaths Tied to 1970s IV Drug Use

Man Contracts Hepatitis A Despite Vaccination

Age at Infection Influences Outcome of Hepatitis C

Hepatitis E Vaccine Recommended For Patients With Chronic Liver Disease

Hepatitis C May Cause Erectile DysfunctionUpdate of Progress on New Drugs - Including Albuferon for HCV

Clinical Trials of Monoclonal Antibody for HCV

Interferon Helps Prevent Liver-Related Deaths for Hepatitis C Patients

Chinese Drug Said Effective and Safe in Treating Chronic Hepatitis C

Once-Promising Drug Found Ineffective in Treating Hepatitis D 

---

September 2002

---

Final NIH Consensus Statement
Read the final report recently issued on the NIH Consensus Development Conference on the Management of Hepatitis C 2002. This important document will drive current and future approaches to the management and care of HCV.

The Business of Organ Transplants

Researchers develop model to predict post-transplant survival in liver transplant patients

New techniques may boost tolerance of donor organs

Early Study Results Show New Interferon Effective for Hepatitis C

Study Finding Pegylated Interferon Superior Said Flawed

Maxim Advances Enrollment of Ceplene Phase 2 Clinical Trial

Oklahoma Hospital Nurse Reused Needles on Patients

GenOdyssee Announces Positive Results of Proprietary Interferon-alpha Variants for the Treatment of Hepatitis C and Cancer

Roche's ribavirin Copegus available in all EU Countries within months
Hepatitis C drug completes Mutual Recognition Procedure in the European
Union

Deaths of Hepatitis C Patients in Japan Prompt Label Change in Rebetol

Pegasys + Ribavirin: study results published

---

October 2002

---

6 Infected by Organ Donor

Battleground: Schering and Roche Duke It Out Over the Huge Hepatitis C Market As Concerns Arise for Some Patients

PEG-Intron Pen Introduced in Europe

Injection Drug Users Continue Risky Habits Even After Testing Positive for Hepatitis C Virus

Acetaminophen (Tylenol) Liver Damage "Is it safe for me to take Tylenol?"

VIRACEPT(R) Appears to be Generally Well Tolerated In Hepatitis-C Co-Infected Patients

Herbal hope for liver disease

Chronic or Primary HCV Infection 

Risk of GI symptoms with over-the-counter nonsteroidal anti-inflammatory drugs
FDA Meeting May Mean Roadblock for Roche

Warning Issued on Reuse of Needles

InterMune, Inhale to develop hepatitis C drug

'Invisible Condom' May Prevent HIV and Herpes

Device extends liver cancer patients' lives-study

FDA Approves Pegasys

Spontaneous Recovery from Hepatitis C Infection Higher Than Thought

High proportion of untreated chronic hepatitis C patients suffers emotional distress
2005-Pegylated form of Infergen
How many patients are being treated with interferon-based antiviral therapies ?

---

March 2002

---

America's Blood Centers Supports FDA Approval Of Nucleic Acid Testing

ICN Pharmaceuticals Defends Ribavirin Patient

Maxim says drug can stop liver damage from alcohol
Flumazenil improves hepatic encephalopathy in patients with cirrhosis
Study: Better Quality of Life With Pegylated Interferon

EPA Approves Disinfectant to Fight Spread of Hepatitis B

Study: Hepatitis C Does Not Up Risk of Death in First 10 Years
Study: Wine Daily Ups Liver Cancer Risk for Hepatitis Patients

Study: Hepatitis C Patients Not on Antiviral Therapy More Depressed

Roche Expects Approval of Pegasys in 2002

US Panel Advises Tattooed and Pierced Not Give Blood
North Shore-LIJ Physician Is Lead Author of Hepatitis C

Study; Results Indicate New Drug Therapy Improves Adherence and Cure Rate

New Molecular Tests Make It Easier to Measure Hepatitis Viral Load

New Research Encouraging on Hepatitis B Combination Therapy

Rivarin-High Dose Interferon Combination Improves Responses In Hepatitis C

Pamela Anderson-Living with Hepatitis C

---

April 2002

---

Sharing Injection Equipment Spreads Hepatitis C

GenPhar Announces Novel Vaccines for HIV, Hepatitis B, Hepatitis C, and Marburg Viruses Doctor Called Likely Source of Hepatitis in Patients
Study: Low-Income Young Women in San Francisco Have High Hepatitis C Rate
Study: Hepatitis A Vaccination Recommended for Hepatitis C Patients
α-Fetoprotein Levels Predictive of Hepatocellular Carcinoma Recurrence
Study confirms Importance of Interferon Sensitivity-Determining Region in HCV Genotype 1 Responsiveness
Study: Smoking, Alcohol Increase Liver Problems for Hepatitis C Patients
Study: Transmission of Hepatitis C From Doctor to Patient "Rare"
New Study to Evaluate HAART in Treating Co-Infected Hepatitis C, HIV Patients
Pegasys Plus Ribavirin Produces Highest Sustained Virological Response (SVR) Rate Ever Achieved for Patients with HCV Genotype 1
Low White Blood Cell and Platelet Counts Are Common with HCV
HCV Activists Criticize Schering's "Access Assurance" Program for PEG-Intron
One of our own speaks out in Washington

---

May 2002   

---

   2002 HCV Related Plenary Highlights from DDW

May News Stories 2002

New Investigational Studies Report on CellCept Use in Patients Who Are Re-Infected With Hepatitis C After a Liver Transplant
Hepatitis C Treatment Slows Liver Damage
Ribozyme Pharmaceuticals Announces Clinical Trials Update and Conference Call
Phase II Study of Heptazyme Slowed Following Loss of Vision in an Animal
Study: PEG-Interferon and Ribavirin Slow Liver Fibrosis in Hepatitis C Patients
Tacrolimus-Associated Diabetes Has Hepatitis C Connection
Liver Disease Varies With Age In Hepatitis C-Infected Drug Users
Patients With Hepatitis C Must Be Discouraged From Drinking Alcohol
Markov Method Quantifies Fibrosis Progression In Hepatitis C
Study: Lamivudine May Delay Transplant Need for Some Hepatitis B Patients
6 Local Deaths Lead to Plasma Warning
Severe Liver Disease Is Uncommon Within the First 2 Decades of HCV Infection

---

June 2002

---

European Hepatitis C Patients Sought for Phase II Trial of Ceplene in Combo Therapy

Study: Hereditary Hemochromatosis With Hepatitis C Ups Risk of Cirrhosis and Fibrosis

Study: Shorter Induction Combo Therapy Appears as Effective for Hepatitis C

Study: IND-6556 May Improve Liver Enzymes in Some Hepatitis C Patients

Study: Peg-Intron Superior to Colchicine for Hepatitis C Patients With Advanced Cirrhosis

Study: No Significant Difference in Side Effects for Weight-Based Doses of Rebetol

Hepatitis C May Be Transmitted Via Toothbrushes

Schering Canada Inc. - Pegetron(TM) Receives Health Canada Approval for the
Treatment of Chronic Hepatitis C

---

January 2001

---

Hepatitis C Infection More Prevalent in Lupus Patients Than Healthy Controls
Heavy Alcohol Use Greatly Increases Cirrhosis Risk in Hepatitis C-Infected Patients
FDA Approves Hepatitis C Therapy 

---

February 2001

---

Daily Interferon Alfacon-1 Treatment with Ribavirin Appears Promising For HCV Infection
SciClone sees Zadaxin launch in U.S. end 2003, early 2004
HCV Viremia at Delivery a Risk Factor for Mother-to-Infant Transmission

---

March 2001

---

Drug helps depression during interferon treatments
Titan Pharmaceuticals Initiates Clinical Testing of Pivanex(R) For Hepatic Tumors
Human Genome Sciences Begins Phase I Clinical Trial of Albuferon in Hepatitis C Patients  

---

April 2001

---

ACG Clinical Implications: Hepatitis in the New Millennium; Hepatitis C Monitoring Tests Advance with Treatment
Study Illuminates How Hepatitis C Infects Cells
Maxim Reports 72-Week Results From Completed Phase 2 Hepatitis C Study Demonstrating Benefit of Treatment With Ceplene
Pegylated Interferon's, Improved Molecular Tools Brighten Potential Outcomes for Patients With Hepatitis

---

May 2001

---

Schering-Plough Reports Interim Results of PEG-INTRON(TM) Plus REBETOL(R) Studies in Hepatitis C Patients at Digestive Diseases Week Meeting
Rate of Hepatitis C Liver Disease May Be More Rapid Than Previously Indicated
PEGASYS(R) (peginterferon Alfa-2a) Studied in Post-Liver Transplant Patients With Recurrent Hepatitis C Infection
Conference Report: Hepatitis C Infection -- Optimizing Treatment, Patient Management, and Basic Aspects

---

June 2001

---

Interferon Prevents Liver Cancer, But Not Mortality, In Hepatitis C Cirrhosis
Hepatitis C Virus Genotype Linked To Cirrhosis Transjugular renal biopsy feasible for patients with liver disease
Antisense Drug Demonstrates Substantial Reduction Of Viral Load in Patients With Drug Resistant Hepatitis C Virus

---

July 2001

---

Twice-Daily Interferon-Beta No Better Than Once-Daily Dosing for Hepatitis C
Schering-Plough Announces FDA Approval to Market REBETOL(R) (Ribavirin, USP) Capsules Separately For Use in Combination With INTRON(R) A for Chronic Hepatitis C
Roche Licenses Potential Second-Generation Drug From ICN to Set New Standards In Hepatitis C Treatment
XTL Biopharmaceuticals Initiates Phase I Clinical Trial with XTL-002 for Hepatitis C

---

 August 2001

---

Hepatitis C Subtype Determines Interferon Responsiveness Factors
Bio-Rad Enters New Territories for Hepatitis C Testing: Company Expands HCV License With Ortho/Chiron
Three Rivers Pharmaceuticals Seeks Permission For Generic Treatment for Hepatitis C

---

 September 2001

---

Daily High-Dose Interferon Induction Therapy Not Advantageous in Hepatitis C
Peginterferon Regimen Outperforms Standard Treatment for Chronic Hepatitis C
Some Blood Donors Get Bad News
Discovers Novel Hepatitis 'C' Target; Drug Development Program

---

 October 2001

---

Quick Treatment Can Cure Hepatitis C
Drug May Limit Liver Damage Caused by Hepatitis C
"UNBUNDLED" REBETOL (RIBAVIRIN) FOR THE TREATMENT OF HEPATITIS C
New Treatment Stops Liver Scarring in Mice  November 2001

Maxim Pharmaceuticals to Initiate Phase 2 Clinical Trial of Ceplene in Triple Combination Therapy for Hepatitis C
Maxim Reports Results From Hepatitis C Pilot Study of Ceplene Triple-Drug Therapy At AASLD Conference
BioMedicines Presents Promising Results from Phase II Trials Of Omega Interferon for the Treatment of Hepatitis C
99% OF PATIENTS REMAIN FREE OF HEPATITIS C VIRUS WHEN TESTED THREE YEARS LATER
Three Rivers Counter-Sues Schering Corporation Over Ribavirin
Effectiveness of Hepatitis C Drug Can Now Be Determined Sooner; VCU Physician Co-Authors New Study Analysis, Says Findings May Improve Patient Care
CN Presents New Data on Viramidine(TM) and Levovirin(TM) At The AASLD Annual Meeting
Effects of the Human Genome Project in 2002
FDA Warns Against Dietary Supplement

---

December 2001

---

Risk of sexual transmission of HCV is low between spouses
Risk factors for the presence of varices in cirrhotic patients are identified
HBV and HCV Prevalence is higher in Crohn's Patients
Acute leukemia can occur after liver transplantation
Ribavirin Antiviral Drug Works by Causing "Genetic Meltdown"
CD-Based Tool Boosts Rural Doctors' Comfort Level With Hepatitis C Patients
Slowing diseases, New and Old
Genetic engineering and the world health crisis